EGFR and non-small cell lung carcinoma: Osimertinib is the only third‐generation epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) approved by the Food and Drug Administration, which has led to a breakthrough in the treatment of patients with advanced EGFR‐mutated non‐small cell lung cancer (NSCLC).1, 2